Select Page

Cancer Drug Pipeline Information for Patient Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained on this website is not a comprehensive list. While we make reasonable efforts to present current and accurate information on this website, this website could include inaccuracies or typographical errors. We do not guarantee and are not responsible for the quality, currency, propriety, accuracy, or reasonableness of any information on this website. Please contact info@canceraction.ca with any inquiries about the terms of use.

Brand NameGeneric NameManufacturerTumour SiteIndicationRoute of AdministrationInformation Source
MasivetmasitinibAB ScienceGastrointestinalRelapsed metastatic colorectal cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalMetastatic pancreatic cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, first-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceMelanomaMetastatic melanoma with JM mutation of c-KITOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, second-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGynecologyRelapsed advanced / metastatic epithelial ovarian cancer patients in second line refractory to first line platinum treatment or in third lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGenitourinaryMetastatic Castrate Resistant Prostate Cancer in first lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceLymphomaRelapsed or refractory peripheral T-cell lymphomaOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
VenclextavenetoclaxAbbVieLeukemiaChronic lymphocytic leukemia (CLL), relapsed-refractory and first lineOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaFollicular Lymphoma (FL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaDiffuse Large B-Cell Lymphoma (DLBCL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
veliparibAbbVieLungOvarian cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieBreastBreast cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieLungLung cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, third lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, first lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer,second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieGastrointestinalPancreatic cancerOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaMarginal zone lymphoma (MZL), relapsed/refractoryOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaDiffuse large B-cell lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaFollicular lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma treatment naïveIntravenoushttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
depatuxizumab mafodotinAbbVieNeurologicalGlioblastoma MultiformeIntravenoushttps://www.abbvie.com/our-science/pipeline/depatuxizumab-mafodotin.html
Imlygictalimogene laherparepvecAmgenMelanomaUnresected metastatic melanomaSubcutaneoushttp://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=talimogene+laherparepvec
XgevadenosumabAmgenOtherAdults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbiditySubcutaneoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
KyproliscarfilzomibAmgenMyelomaMultiple myeloma, in combination with chemotherapyIntravenoushttp://www.amgenpipeline.com/pipeline/
KyproliscarfilzomibAmgenLungSmall-cell lung cancerIntravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLeukemiaPhiladelphia Positive/BCR-ABL Positive Acute Lymphoblastic LeukemiaIntravenoushttp://www.amgenpipeline.com/pipeline/
encorafenibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with binimetinibOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
encorafenibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer in combination with binimetinib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
binimetinibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer, in combination with encorafenib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
binimetinibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with encorafenibOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
zolbetuximab (IMAB362)Astellas PharmaGastrointestinalGastroesophageal adenocarcinomaIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
gilteritinib (ASP2215)Astellas PharmaLeukemiaAcute myeloid leukemiaOralhttps://www.astellas.com/jp/en/investors/ir-library/pipeline
enfortumab vetodinAstellas PharmaGenitourinaryUrothelial cancerIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
ASG-16C3FAstellas PharmaGenitourinaryRenal cell carcinomaIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
savolitinibAstraZenecaGenitourinaryPapillary renal cell carcinomahttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungAdjuvant EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGenitourinaryProstate cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGynecologyFirst line BRCAm ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA adjuvant breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGastrointestinalPancreatic cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
moxetumomab pasudotoxAstraZenecaLeukemiaHairy cell leukaemiaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalGastric cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalMetastatic pancreatic ductal carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalHepatocellular carcinomaIntravenoushttps://www.astrazeneca.com/our-science/pipeline.html
durvalumab + tremelimumabAstraZenecaLung3rd-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGenitourinary1st-line bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck2nd-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck1st-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
cediranibAstraZenecaGynecologyRecurrent platinum resistant ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD6738AstraZenecaGastrointestinalGastric cancer, in combination with olaparibhttps://www.astrazeneca.com/our-focus-areas/oncology.html
capivasertibAstraZenecaBreastBreast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD1775AstraZenecaGynecologyOvarian cancer, in combination with chemotherapyhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLymphomaB-cell malignancyOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaRelapsed/refractory chronic lymphocytic leukemia and high riskOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
Radium-223 dichlorideBayerBreastbone metastasis in breast cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryCastration-resistant prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryhormone sensitive prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaNon Hodgkin LymphomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomarelapsed follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm576098.htm
xentuzumabBoehringer IngelheimBreastMetastatic breast cancerhttps://www.inoncology.com/our-compounds
xentuzumabBoehringer IngelheimGenitourinaryCastration-resistant prostate cancerhttps://www.inoncology.com/our-compounds
VargatefnintedanibBoehringer IngelheimLungAdvanced non‑small cell lung cancer Oralhttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimLungSquamous Non-Small Cell Lung Cancer Oralhttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimHead and NeckRecurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum‑based therapyOralhttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimGenitourinaryadvanced platinum-refractory urothelial cancerOralhttps://www.inoncology.com/our-compounds
OpdivonivolumabBristol-Myers SquibbGastrointestinalmismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm
ThalomidthalidomideCelgeneMyelomaNewly diagnosed multiple myelomaOralhttps://www.celgene.com/research-development/
IstodaxromidepsinCelgeneLymphomaFirst-line peripheral T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
IstodaxromidepsinCelgeneLymphomaCutaneous T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
CC-486CelgeneOtherLower-risk myelodysplastic syndromeOralhttps://www.celgene.com/research-development/
oral azacitidine (CC-486)CelgeneOtherMyelodysplastic syndromeOral
oral azacitidine (CC-486)CelgeneLungAdvanced non-small cell lung cancerOral
oral azacitidine (CC-486)CelgeneBreastMetastatic breast cancerOral
Abraxanenab-paclitaxelCelgeneGastrointestinalAdjuvant therapy for pancreatic cancerIntravenous
marizomibCelgeneNeurologicalGlioblastoma multiformehttps://www.celgene.com/research-development/
luspaterceptCelgeneOtherMyleodysplastic syndromeSubcutaneoushttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaFirst-line diffuse large B-cell lymphoma (ABC-subtype)Oralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaRelapsed/refractory indolent lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaFirst-line follicular lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaMantle cell lymphoma (relapsed/refractory)Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
durvalumabCelgeneLeukemiaAcute myeloid leukemia (AML)Intravenous
durvalumabCelgeneOtherMyleodysplastic syndromeIntravenous
CC-486CelgeneLeukemiaPost-induction acute myeloid leukemia maintenanceIntravenoushttps://www.celgene.com/research-development/
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (20-30% blasts)Intravenous
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (>30% blasts)Intravenous
Vidazaazacitidine for injectionCelgeneOtherMyelodysplastic syndromesIntravenous
RubracarucaparibClovis OncologyGynecologyDeleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapiesOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
MORAb-004EisaiMelanomaMelanomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalHepatocellular carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalBiliary tract cancerOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryFirst-line renal cell carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
farletuzumabEisaiGynecologyPlatinum-sensitive ovarian cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
HalaveneribulinEisaiGenitourinaryUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Intravenous https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm
HalaveneribulinEisaiBreastTriple negative Breast cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
amatuximabEisaiLungMesotheliomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
CyramzaramucirumabEli LillyGastrointestinalMetastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimenIntravenoushttp://wayback.archive-it.org/7993/20170111231635/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
CyramzaramucirumabEli LillyGastrointestinalGastric cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
CyramzaramucirumabEli LillyGastrointestinalHepatocellular carcinoma, second-line treatment Intravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalAdvanced gastric or gastroesophageal junction adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidineIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalMetastatic gastric or gastroesophageal junction adenocarcinomaIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxelIntravenoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer, EGFR mutation, previously untreatedIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGenitourinaryUrothelial carcinomaIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
prexasertibEli LillyLungSmall cell lung cancer Intravenoushttp://lillyoncologypipeline.com/cancer-type
necitumumabEli LillyLungSquamous non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
merestinibEli LillyGastrointestinalFirst-line advanced or metastatic biliary tract cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
LY3023414Eli LillyGenitourinaryProstate cancerOralhttp://lillyoncologypipeline.com/cancer-type
VerzenioabemaciclibEli LillyGastrointestinalPancreatic cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
VerzenioabemaciclibEli LillyLungSquamous non-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
VerzenioabemaciclibEli LillyBreastPostmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer, with anastrozole or fulvestrantOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
VerzenioabemaciclibEli LillyNeurologicalPatients with brain metastases secondary to hormone-receptor-positive breast cancer, non-small cell lung cancer, or melanomaOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
tepotinibEMD SeronoGastrointestinalHepatocellular cancerOralhttps://www.emdserono.com/us-en/research.html
tepotinibEMD SeronoLungNon-small cell lung cancerOralhttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGastrointestinalGastric cancer, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGynecologyOvarian cancer, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoHead and NeckLocally advanced head and neckIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoLungNon-small cell lung cancerIntravenoushttps://www.emdserono.com/us-en/research.html
BavencioavelumabEMD SeronoGenitourinaryRenal cell carcinoma, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
CometriqcabozantinibExelixisGastrointestinalColorectal cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
BavencioavelumabEMD SeronoGenitourinaryUrothelial cancer. first lineIntravenoushttps://www.emdserono.com/us-en/research.html
CometriqcabozantinibExelixisGastrointestinalHepatocellular cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaSoft tissue sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastBreast cancer patients with brain metastasesOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastMetastatic, hormone-receptor positive breast cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisLungNon-small cell lung cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyEndometrial cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaHigh grade uterine sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaRelapsed osteosarcoma or Ewing sarcomasOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisEndocrineDifferentiated thyroid cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGenitourinaryRenal cell cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
ZelborafvemurafenibGenentechEndocrinePapillary thyroid cancer, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
CometriqcabozantinibExelixisGenitourinaryBladder cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastTriple negative breast cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic pancreatic cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeuroendocrine and carcinoid tumorsOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic gastrointestinal stromal tumorOralhttps://www.exelixis.com/cabozantinib-development-program/
ErivedgevismodegibGenentechOtherOperable basal cell carcinomaOralhttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast1st line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast3rd line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
RITUXAN HYCELArituximab and hyaluronidase humanGenentechLeukemiafollicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemiaIntravenous
polatuzumab vedotinGenentechLymphomaNon-Hodgkin's lymphoma and diffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastEarly HER2-positive breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreast2nd line HER2-negative breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLeukemiaFront-line chronic lymphocytic leukemiaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaDiffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalGastric cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechBreastTriple-negative breast cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalProstate cancerOralhttps://www.gene.com/medical-professionals/pipeline
TecentriqatezolizumabGenentechGenitourinaryFor locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
tirabrutinibGilead SciencesLymphomaB-cell malignanciesOralhttp://www.gilead.com/research/pipeline
entospletinibGilead SciencesLeukemiaHematological MalignanciesOralhttp://www.gilead.com/research/pipeline
andecaliximabGilead SciencesGastrointestinalGastric CancerSubcutaneoushttp://www.gilead.com/research/pipeline
VenclextavenetoclaxHoffmann-La RocheLeukemiaFrontline chronic lymphocytic leukemia, in combination with GazyvaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiamyelodysplastic syndromes, first-line treatment, in combination with azacitidineOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheMyelomaRelapsed or refractory multiple myelomaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaRelapsed/refractory follicular lymphoma, in combination with rituximabOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatment, in combination with PerjetaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastThird line HER2-positive metastatic breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
polatuzumab vedotinHoffmann-La RocheLeukemiaFirst line Diffuse Large B-cell LymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
PerjetapertuzumabHoffmann-La RocheBreastEarly HER2-positive breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, new-adjuvant treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
idasanutlinHoffmann-La RocheLeukemiaAcute myeloid leukemiaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
codrituzumabHoffmann-La RocheGastrointestinalMetastatic liver cancerhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumab + vemurafenibHoffmann-La RocheMelanomaBRAFv600 mutation-positive advanced melanoma, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheBreastFirst line metastatic triple negative breast cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGynecologyOvarian cancer, front-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patientsIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell cancer, in combination with AvastinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without AvastinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungNon-small cell lung cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line squamous non-small cell lung cancer, combination regimen with chemotherapyIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryMuscle-invasive bladder cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryFirst-line metastatic urothelial carcinomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapyIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexedIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst line extensive-stage small cell lung cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastMetastatic triple-negative breast cancer, first-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
YondelistrabectedinJanssenGynecologyRelapsed ovarian cancerIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia, in combination with obinutuzumabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia (young and fit), in combinaction with rituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaTreatment naive patients with mantle cell lymphoma, in combination with Bendamustine and RituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaNewly diagnosed non-germinal centre B-cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with bortezomib, melphalan and prednisoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with lenalidomide and low-dose dexamethasoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-eligible patients, in combination with velcade, thalidomide and dexamethasomeIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
apalutamide + abiraterone acetateJanssenGenitourinaryMetastatic castration-resistant chemotherapy-naïve prostate cancerOral
apalutamideJanssenGenitourinaryMetastatic hormone-sensitive prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryLocalized prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
ZytigaabirateroneJanssenGenitourinaryNewly Diagnosed Hormone Naïve Metastatic Prostate Cancer Oralhttp://www.janssen.com/research-and-development/product-pipeline
Vyxeosliposome-encapsulated combination of daunorubicin and cytarabine Jazz PharmaceuticalLeukemianewly diagnosed high risk AMLIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm
KeytrudapembrolizumabMerckGastrointestinalEsophogeal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalrecurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
KeytrudapembrolizumabMerckGastrointestinalColorectal CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalLiver cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyOvarian CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckBreastBreast cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyRenal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryProstate cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckNasopharyngeal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckRecurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm
KeytrudapembrolizumabMerckMyelomaMultiple myelomaIntravenous
OdomzosonidegibNovartisOtherlocally advanced basal cell carcinomaOralhttp://wayback.archive-it.org/7993/20170111231633/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
KisqaliribociclibNovartisBreastBreast cancer, in combination with Everolimus + Exemestane or in combination with fulvestrantOral
FarydakpanobinostatNovartisMyelomaMultiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agentOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
ArzerraofatumumabNovartisLeukemiaFor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
EGF816NovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
capmatinibNovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
alpelisibNovartisBreastBreast Cancer (HR+, HER2-)Oralhttps://www.novartis.com/our-company/novartis-oncology
talazoparibPfizerBreastGermline BRCA-mutated metastatic breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
SutentsunitinibPfizerGenitourinaryadjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.htm
IbrancepalbociclibPfizerBreastHigh-risk early breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastEarly breast cancer in adjuvant settingOralhttps://www.pfizer.com/science/drug-product-pipeline
lorlatinibPfizerLungALK non-small cell lung cancer, first line and second lineOralhttps://www.pfizer.com/science/drug-product-pipeline
glasdegibPfizerLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.pfizer.com/science/drug-product-pipeline
Mylotarggemtuzumab ozogamicinPfizerLeukemiaAcute Myeloid LeukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm
XtandienzalutamidePfizerGastrointestinalHepatocellular carcinomaOralhttps://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryMetastatic hormone sensitive prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
dacomitinibPfizerLungFirst-line EGFR-mutant non-small cell lung cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
XalkoricrizotinibPfizerLungROS1-positive metastatic non-small cell lung cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
BosulifbosutinibPfizerLeukemiaChronic myelogenous leukemia, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589856.htm
InlytaaxitinibPfizerGenitourinaryRenal cell carcinoma, adjuvant therapy in combination with pembroliumab Oralhttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerHead and NeckLocally Advanced Squamous Cell Carcinoma of the Head and NeckIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, second lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyOvarian cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
NerlynxneratinibPuma Biotechnology Inc.Breastfor the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm
LibtayocemiplimabSanofiSkinAdvanced cutaneous squamous cell carcinomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
LibtayocemiplimabSanofiSkinAdvanced basal cell carcinomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
LibtayocemiplimabSanofiLungNSCLC, first lineIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
isatuximabSanofiMeylomaRelapsed refractory multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
tisotumab vetodinSeattle GeneticsGenitourinaryCervical cancerhttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline mature T-cell lymphomasIntravenoushttp://www.seattlegenetics.com/pipeline/brentuximab-vedotin
BavencioavelumabEMD SeronoOtherMerkel cell carcinoma, first lineIntravenoushttps://www.emdserono.com/us-en/research.html
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaRelapsed non-Hodgkin lymphomaIntravenoushttp://www.seattlegenetics.com/pipeline
sapanisertibTakedaBreastBreast cancerOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
IclusigponatinibTakedaLeukemiaPh+Acute lymphoblastic leukemia (ALL)Oralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaAmyloidosisOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
ZejulaniraparibTesaro, Inc.Gynecologymaintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaindolent NHLIntravenoushttp://www.gilead.com/research/pipeline
YescartaAxicabtagene ciloleucel Kite PharmaceuticalsLymphomarelapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm581296.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm
CabometyxcabozantinibIpsen PharmaGastrointestinalHepatocellular carcinoma, second lineOralhttps://www.ipsen.com/research-development/pipeline/
VerzenioabemaciclibEli LillyBreastHigh-Risk, Node-Positive, Early-Stage, Hormone-Receptor-Positive, HER 2-Negative Breast Cancer, adjuvant therapyOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
XtandienzalutamidePfizerGenitourinaryNon-metastatic hormone sensitive, high risk, prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
VerzenioabemaciclibEli LillyBreastin combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm578081.htm
LibtayocemiplimabSanofiGynecologyCervical cancerIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaprimary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
SpryceldasatinibBristol-Myers SquibbLeukemiapediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phaseOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584725.htm
BlincytoblinatumomabAmgenLeukemiaRelapsed/Refractory (R/R) Aggressive B-Cell NHLIntravenoushttp://www.amgenpipeline.com/pipeline/
IclusigponatinibTakedaLeukemiaChronic phase Chronic Myeloid Leukemia (CML)https://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma, front lineOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
pevonedistatTakedaLeukemiaLow-Blast Acute Myelogenous LeukemiaIntravenoushttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-659TakedaLymphomaDiffuse large B-cell lymphomaOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
KTE-C19Gilead SciencesLymphomaMCLIntravenoushttp://www.gilead.com/research/pipeline
CalquenceacalabrutinibAstraZenecaLeukemiaMantle cell lymphoma, after at least one prior therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm
asciminib (ABL001)NovartisLeukemiaChronic Myeloid LeukemiaOralhttps://www.novartis.com/our-company/novartis-oncology
ladiratuzumab vedotin (SGN-LIV1A)Seattle GeneticsBreastBreast cancerhttp://www.seattlegenetics.com/pipeline
enfortumab vedotin Seattle GeneticsGenitourinarymetastatic urothelial cancer Intravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomapreviously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm601947.htm
TecentriqatezolizumabHoffmann-La RocheBreastAdjuvant triple-negative breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabGenentechLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechGastrointestinalHER2-positive gastric cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
ZelborafvemurafenibGenentechMelanomaAdjuvant metastatic melanoma, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
Lutatheralutetium Lu 177 dotatateAdvanced Accelerator Applications USA, IncOtherreceptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm594105.htm
NinlaroixazomibTakedaMyelomaMultiple myeloma, relapsed/refractory, doublet regimenOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance therapy, with or without transplantOralhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
ZytigaabirateroneJanssenGenitourinaryin combination with prednisone for metastatic high-risk castration-sensitive prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596015.htm
VerzenioabemaciclibEli LillyBreastin combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm598404.htm
talazoparibPfizerGenitourinaryMetastatic castration-resistant prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
Onivydeirinotecan liposomeIpsen PharmaGastrointestinalPancreatic ductal adenocarcinomab (PDAC)Intravenoushttps://www.ipsen.com/research-development/pipeline/
Onivydeirinotecan liposomeIpsen PharmaLungSmall Cell Lung cancer (SCLC), second lineIntravenoushttps://www.ipsen.com/research-development/pipeline/
KeytrudapembrolizumabMerckLungSmall Cell Lung cancer (SCLC)Intravenoushttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGastrointestinalPancreatic cancerOralhttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGenitourinaryProstate cancerOralhttps://www.merck.com/research/pipeline/home.html
isatuximabSanofiLymphomaNewly diagnosed multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
BlincytoblinatumomabAmgenLeukemia B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603171.htm
telisotuzumab vedotinAbbVieLungNon-small cell lung cancerIntravenoushttps://www.abbvie.com/our-science/pipeline/abbv-399.html
tislelizumabCelgeneLungNon-small cell lung cancerIntravenoushttps://www.celgene.com/research-development/
tislelizumabCelgeneGastrointestinalHepatocellular carcinomaIntravenoushttps://www.celgene.com/research-development/
tislelizumabCelgeneGastrointestinalEsophageal squamous cell carcinomaIntravenoushttps://www.celgene.com/research-development/
Liso-cel, JCAR017CelgeneLymphomaLarge B-Cell LymphomaIntravenoushttps://www.celgene.com/research-development/
LenvimalenvatinibEisaiGynecologicalendometrial carcinomaboral https://www.eisai.com/company/business/research/pdf/epipeline.pdf
CyramzaramucirumabEli LillyGenitourinaryBladder cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/III
LartruvoolaratumabEli LillySarcomaAdvanced Soft Tissue Sarcoma, in combination with gemcitabine and docetaxelIntravenoushttp://lillyoncologypipeline.com/molecule/pdgfr-alpha-antibody/trials
pegilodecakinEli LillyGastrointestinalPancreatic cancerSubcutaneoushttp://lillyoncologypipeline.com/clinical-phase/III
prexasertibEli LillyGynecologicalPlatinum-Resistant or Refractory Recurrent Ovarian CancerIntravenoushttp://lillyoncologypipeline.com/cancer-type
pegilodecakinEli LillyLungNon-small cell lung cancerSubcutaneoushttp://lillyoncologypipeline.com/clinical-phase/II
abituzumabEMD SeronoGastrointestinalColorectal CancerOralhttps://www.emdserono.com/us-en/research.html
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumabHoffmann-La RocheMelanomaBRAF wild type metastatic melanoma, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
entrectinibGenentechLungNon-small cell lung canceroralhttps://www.gene.com/medical-professionals/pipeline
entrectinibHoffmann-La RocheLungNon-small cell lung canceroralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
tiragolumabGenentechLungNon-small cell lung cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
polatuzumab vedotinHoffmann-La RocheLymphomaFollicular lymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CometriqcabozantinibExelixisGenitourinaryProstate cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyOvarian cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisMyelomaMultiple myeloma, in combination with carfilzomibOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisHead and NeckSquamous cell carcinoma of the head and neckOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeurofibromasOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalpediatriac gliomaOralhttps://www.exelixis.com/cabozantinib-development-program/
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaDiffuse large B-cell lymphomaIntravenoushttp://www.gilead.com/research/pipeline
AlecensaalectinibHoffmann-La RocheLungALK+ non-small cell lung cancer, adjuvantOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first line in combination with nivolumabOralhttps://www.ipsen.com/research-development/pipeline/
DarzalexdaratumumabJanssenMyelomaSmoldering multiple myelomaIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaRelapsed/refractory multiple myeloma, in combination with pomalidomideIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
KeytrudapembrolizumabMerckSkinCutaneous squamous cell carcinomaIntravenoushttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckGynecologicalEndometrial canceroralhttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckGastrointestinalBiliary tract canceroralhttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckLungNon-small cell lung canceroralhttps://www.merck.com/research/pipeline/home.html
Cavatakcoxsackievirus, CVA21MerckMelanomaMelanomaIntratumoralhttps://www.merck.com/research/pipeline/home.html
IlariscanakinumabNovartisLungNon-small cell lung cancerSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
IlariscanakinumabNovartisLungNon-small cell lung cancer, adjuvant treatmentSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
ArzerraofatumumabNovartisLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLeukemiaChronic lymphocytic leukemiaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLymphomaRelapsed/refractory diffuse large B-cell lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartislymphomaRelapsed/refractory follicular lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, adjuvantOralhttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, pre-menopausal womenOralhttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
RydaptmidostaurinNovartisLeukemiaAcute myeloid leukemia, FLT3 wild typeOralhttps://www.novartis.com/our-company/novartis-oncology
BavencioavelumabPfizerSkinMerkel Cell Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastHER-2 breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
LibtayocemiplimabSanofiLungNSCLC, second lineIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
isatuximab + cemiplimabSanofiMeylomaRelapsed refractory multiple myelomaIntravenoushttps://www.sanofi.com/en/science-and-innovation/research-and-development
TAK-931TakedaGastrointestinalMetastatic colorectal cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
TAK-931TakedaLungNon-small cell lung cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/
relugolixTakedaGenitourinaryprostate cancerhttps://www.takeda.com/what-we-do/research-and-development/our-pipeline/

YesNo